Click for best price
Postpemic Era Anal Colorectal Cancer Market Size, Share 2022
Summary
The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.
2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.
According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.
(Post-pandemic Era)-Global Anal and Colorectal Cancer Market Segment Research Report 2022?, which aims to sort out the development status and trends of the Anal and Colorectal Cancer industry at home and abroad, estimate the overall market scale of the Anal and Colorectal Cancer industry and the market share of major countries, Anal and Colorectal Cancer industry, and study and judge the downstream market demand of Anal and Colorectal Cancer through systematic research, Analyze the competition pattern of Anal and Colorectal Cancer, so as to help solve the pain points of various stakeholders in Anal and Colorectal Cancer industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.
Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Anal and Colorectal Cancer Market by Research Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Anal and Colorectal Cancer Market?
Abbott Diagnostics
Advaxis
Abbott
Amgen
Atara Biotherapeutics
Bayer
Metabiomics
Beckman Coulter
BeiGene
Boehringer Ingelheim
Clinical Genomics
EDP Biotech
Eli Lilly
Epigenomics
Exact Sciences
Genomictree
Immunovaccine
ISA Pharmaceuticals
Merck
Major Type of Anal and Colorectal Cancer Covered in Research report:
Surgery
Radiation therapy
Colorectal cancer chemotherapy
Targeted therapy
Immunotherapy
Application Segments Covered in Research Market
Hospitals
Ambulatory surgery centers
Cancer research centers
For any other requirements, please feel free to contact us and we will provide you customized report.
| Report Attributes |
Report Details |
| Report Title |
(Post-pandemic Era)-Global Anal and Colorectal Cancer Market Segment Research Report 2022 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
115 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
Table of Contents
Global Anal and Colorectal Cancer Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Anal and Colorectal Cancer Market by Value
2.2.1 Global Anal and Colorectal Cancer Revenue by Type
2.2.2 Global Anal and Colorectal Cancer Market by Value (%)
2.3 Global Anal and Colorectal Cancer Market by Production
2.3.1 Global Anal and Colorectal Cancer Production by Type
2.3.2 Global Anal and Colorectal Cancer Market by Production (%)
3. The Major Driver of Anal and Colorectal Cancer Industry
3.1 Historical & Forecast Global Anal and Colorectal Cancer Demand
3.2 Largest Application for Anal and Colorectal Cancer (2018-2028)
3.3 The Major Downstream Company in China Market 2022
4. Global and Regional Anal and Colorectal Cancer Market
4.1 Regional Market Size in Terms of Production & Demand (2022)
4.2 Regional Market Share in Terms of Revenue (2018-2022)
4.3 Concentration Ratio (CR5& CR10) of Anal and Colorectal Cancer Market
4.4 Mergers & Acquisitions, Expansion Plans
5. US Anal and Colorectal Cancer Production, Demand (2018-2028)
5.1 Current and Estimated Production Breakdown by Type
5.2 Current and Estimated Demand Breakdown by Type
5.3 Current and Estimated Demand Breakdown by Application
5.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
6. Europe Anal and Colorectal Cancer Production, Demand (2018-2028)
6.1 Current and Estimated Production Breakdown by Type
6.2 Current and Estimated Demand Breakdown by Type
6.3 Current and Estimated Demand Breakdown by Application
6.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
7. China Anal and Colorectal Cancer Production, Demand (2018-2028)
7.1 Current and Estimated Production Breakdown by Type
7.2 Current and Estimated Demand Breakdown by Type
7.3 Current and Estimated Demand Breakdown by Application
7.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
8. Japan Anal and Colorectal Cancer Production, Demand (2018-2028)
8.1 Current and Estimated Production Breakdown by Type
8.2 Current and Estimated Demand Breakdown by Type
8.3 Current and Estimated Demand Breakdown by Application
8.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
9. India Anal and Colorectal Cancer Production, Demand (2018-2028)
9.1 Current and Estimated Production Breakdown by Type
9.2 Current and Estimated Demand Breakdown by Type
9.3 Current and Estimated Demand Breakdown by Application
9.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
10. Korea Anal and Colorectal Cancer Production, Demand (2018-2028)
10.1 Current and Estimated Production Breakdown by Type
10.2 Current and Estimated Demand Breakdown by Type
10.3 Current and Estimated Demand Breakdown by Application
10.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
11. Southeast Asia Anal and Colorectal Cancer Production, Demand (2018-2028)
11.1 Current and Estimated Production Breakdown by Type
11.2 Current and Estimated Demand Breakdown by Type
11.3 Current and Estimated Demand Breakdown by Application
11.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
12. Global Anal and Colorectal Cancer Average Price Trend
12.1 Market Price for Each Type of Anal and Colorectal Cancer in US (2018-2022)
12.2 Market Price for Each Type of Anal and Colorectal Cancer in Europe (2018-2022)
12.3 Market Price for Each Type of Anal and Colorectal Cancer in China (2018-2022)
12.4 Market Price for Each Type of Anal and Colorectal Cancer in Japan (2018-2022)
12.5 Market Price for Each Type of Anal and Colorectal Cancer in India (2018-2022)
12.6 Market Price for Each Type of Anal and Colorectal Cancer in Korea (2018-2022)
12.7 Market Price for Each Type of Anal and Colorectal Cancer in Southeast Asia (2018-2022)
13. Industrial Chain (Impact of COVID-19)
13.1 Anal and Colorectal Cancer Industrial Chain Analysis
13.2 Downstream
13.3 Impact of COVID-19
13.4 Post-pandemic Era
13.5 Technology Trends of Anal and Colorectal Cancer
14. Anal and Colorectal Cancer Competitive Landscape
14.1 Abbott Diagnostics
14.1.1 Abbott Diagnostics Company Profiles
14.1.2 Abbott Diagnostics Product Introduction
14.1.3 Abbott Diagnostics Anal and Colorectal Cancer Sales, Revenue (2018-2022)
14.1.4 Strategic initiatives
14.2 Advaxis
14.2.1 Advaxis Company Profiles
14.2.2 Advaxis Product Introduction
14.2.3 Advaxis Anal and Colorectal Cancer Sales, Revenue (2018-2022)
14.2.4 Strategic initiatives
14.3 Abbott
14.3.1 Abbott Company Profiles
14.3.2 Abbott Product Introduction
14.3.3 Abbott Anal and Colorectal Cancer Sales, Revenue (2018-2022)
14.3.4 Strategic initiatives
14.4 Amgen
14.4.1 Amgen Company Profiles
14.4.2 Amgen Product Introduction
14.4.3 Amgen Anal and Colorectal Cancer Sales, Revenue (2018-2022)
14.4.4 Strategic initiatives
14.5 Atara Biotherapeutics
14.5.1 Atara Biotherapeutics Company Profiles
14.5.2 Atara Biotherapeutics Product Introduction
14.5.3 Atara Biotherapeutics Anal and Colorectal Cancer Sales, Revenue (2018-2022)
14.5.4 Strategic initiatives
14.6 Bayer
14.6.1 Bayer Company Profiles
14.6.2 Bayer Product Introduction
14.6.3 Bayer Anal and Colorectal Cancer Sales, Revenue (2018-2022)
14.6.4 Strategic initiatives
14.7 Metabiomics
14.7.1 Metabiomics Company Profiles
14.7.2 Metabiomics Product Introduction
14.7.3 Metabiomics Anal and Colorectal Cancer Sales, Revenue (2018-2022)
14.7.4 Strategic initiatives
14.8 Beckman Coulter
14.8.1 Beckman Coulter Company Profiles
14.8.2 Beckman Coulter Product Introduction
14.8.3 Beckman Coulter Anal and Colorectal Cancer Sales, Revenue (2018-2022)
14.8.4 Strategic initiatives
14.9 BeiGene
14.9.1 BeiGene Company Profiles
14.9.2 BeiGene Product Introduction
14.9.3 BeiGene Anal and Colorectal Cancer Sales, Revenue (2018-2022)
14.9.4 Strategic initiatives
14.10 Boehringer Ingelheim
14.10.1 Boehringer Ingelheim Company Profiles
14.10.2 Boehringer Ingelheim Product Introduction
14.10.3 Boehringer Ingelheim Anal and Colorectal Cancer Sales, Revenue (2018-2022)
14.10.4 Strategic initiatives
14.11 Clinical Genomics
14.12 EDP Biotech
14.13 Eli Lilly
14.14 Epigenomics
14.15 Exact Sciences
14.16 Genomictree
14.17 Immunovaccine
14.18 ISA Pharmaceuticals
14.19 Merck
15. Conclusion
16. Methodology and Data Source
LIST OF TABLES & FIGURES
List of Tables and Figures
Figure 1. Total Demand by Application of Anal and Colorectal Cancer Industry (Volume)
Figure 2. Anal and Colorectal Cancer Production & Demand by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2027)
Figure 4. The Top 10 and 5 Players Market Share by Anal and Colorectal Cancer Revenue in 2022
Figure 5. US Anal and Colorectal Cancer Production, Demand (2018-2028)
Figure 6. Production Breakdown by Type (%)
Figure 7. Demand Breakdown by Type (%)
Figure 8. Demand Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Anal and Colorectal Cancer Production, Demand (2018-2028)
Figure 12. Production Breakdown by Type (%)
Figure 13. Demand Breakdown by Type (%)
Figure 14. Demand Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Anal and Colorectal Cancer Production, Demand (2018-2028)
Figure 18. Production Breakdown by Type (%)
Figure 19. Demand Breakdown by Type (%)
Figure 20. Demand Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Anal and Colorectal Cancer Production, Demand (2018-2028)
Figure 25. Production Breakdown by Type (%)
Figure 26. Demand Breakdown by Type (%)
Figure 27. Demand Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Anal and Colorectal Cancer Production, Demand (2018-2028)
Figure 31. Production Breakdown by Type (%)
Figure 32. Demand Breakdown by Type (%)
Figure 33. Demand Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Anal and Colorectal Cancer Production, Demand (2018-2028)
Figure 37. Production Breakdown by Type (%)
Figure 38. Demand Breakdown by Type (%)
Figure 39. Demand Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Anal and Colorectal Cancer Production, Demand (2018-2028)
Figure 43. Current and Estimated Production Breakdown by Type (2018-2028)
Figure 44. Production Breakdown by Type (%)
Figure 45. Demand Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Anal and Colorectal Cancer Revenue, by Type (Million USD) (2018-2028)
Table 4. Anal and Colorectal Cancer Production, by Type (K Unit) (2018-2028)
Table 5. Anal and Colorectal Cancer Demand (K Unit) by Application (2018-2028)
Table 6. Anal and Colorectal Cancer Demand (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Production & Demand (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2027)
Table 10. Ranking of Global Top Anal and Colorectal Cancer Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Anal and Colorectal Cancer Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 13. Current and Estimated Production Breakdown by Type (2018-2028)
Table 14. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 15. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Anal and Colorectal Cancer Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 19. Current and Estimated Production Breakdown by Type (2018-2028)
Table 20. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 21. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Anal and Colorectal Cancer Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 25. Table Current and Estimated Production Breakdown by Type
Table 26. Current and Estimated Demand Breakdown by Type
Table 27. Current and Estimated Demand Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Anal and Colorectal Cancer Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 30. Current and Estimated Production Breakdown by Type (2018-2028)
Table 31. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 32. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Anal and Colorectal Cancer Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 36. Current and Estimated Production Breakdown by Type (2018-2028)
Table 37. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 38. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Anal and Colorectal Cancer Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 42. Current and Estimated Production Breakdown by Type (2018-2028)
Table 43. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 44. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Anal and Colorectal Cancer Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 48. Table Current and Estimated Demand Breakdown by Type (2018-2028)
Table 49. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Anal and Colorectal Cancer in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Anal and Colorectal Cancer in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Anal and Colorectal Cancer in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Anal and Colorectal Cancer in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Anal and Colorectal Cancer in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Anal and Colorectal Cancer in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Anal and Colorectal Cancer in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. Abbott Diagnostics Profiles
Table 61. Abbott Diagnostics Anal and Colorectal Cancer Product Introduction
Table 62. Abbott Diagnostics Anal and Colorectal Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 63. Abbott Diagnostics Strategic initiatives
Table 64. Advaxis Profiles
Table 65. Advaxis Anal and Colorectal Cancer Product Introduction
Table 66. Advaxis Anal and Colorectal Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 67. Advaxis Strategic initiatives
Table 68. Abbott Profiles
Table 69. Abbott Anal and Colorectal Cancer Product Introduction
Table 70. Abbott Anal and Colorectal Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 71. Abbott Strategic initiatives
Table 72. Amgen Profiles
Table 73. Amgen Anal and Colorectal Cancer Product Introduction
Table 74. Amgen Anal and Colorectal Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 75. Amgen Strategic initiatives
Table 76. Atara Biotherapeutics Profiles
Table 77. Atara Biotherapeutics Anal and Colorectal Cancer Product Introduction
Table 78. Atara Biotherapeutics Anal and Colorectal Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 79. Atara Biotherapeutics Strategic initiatives
Table 80. Bayer Profiles
Table 81. Bayer Anal and Colorectal Cancer Product Introduction
Table 82. Bayer Anal and Colorectal Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 83. Bayer Strategic initiatives
Table 84. Metabiomics Profiles
Table 85. Metabiomics Anal and Colorectal Cancer Product Introduction
Table 86. Metabiomics Anal and Colorectal Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 87. Metabiomics Strategic initiatives
Table 88. Beckman Coulter Profiles
Table 89. Beckman Coulter Anal and Colorectal Cancer Product Introduction
Table 90. Beckman Coulter Anal and Colorectal Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 91. Beckman Coulter Strategic initiatives
Table 92. BeiGene Profiles
Table 93. BeiGene Anal and Colorectal Cancer Product Introduction
Table 94. BeiGene Anal and Colorectal Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 95. BeiGene Strategic initiatives
Table 97. Boehringer Ingelheim Profiles
Table 98. Boehringer Ingelheim Anal and Colorectal Cancer Product Introduction
Table 99. Boehringer Ingelheim Anal and Colorectal Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 100. Boehringer Ingelheim Strategic initiatives
Table 101. Clinical Genomics Profiles
Table 102. Clinical Genomics Anal and Colorectal Cancer Product Introduction
Table 103. Clinical Genomics Anal and Colorectal Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 104. Clinical Genomics Strategic initiatives
Table 105. EDP Biotech Profiles
Table 106. EDP Biotech Anal and Colorectal Cancer Product Introduction
Table 107. EDP Biotech Anal and Colorectal Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 108. EDP Biotech Strategic initiatives
Table 109. Eli Lilly Profiles
Table 110. Eli Lilly Anal and Colorectal Cancer Product Introduction
Table 111. Eli Lilly Anal and Colorectal Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 112. Eli Lilly Strategic initiatives
Table 113. Epigenomics Profiles
Table 114. Epigenomics Anal and Colorectal Cancer Product Introduction
Table 115. Epigenomics Anal and Colorectal Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 116. Epigenomics Strategic initiatives
Table 117. Exact Sciences Profiles
Table 118. Exact Sciences Anal and Colorectal Cancer Product Introduction
Table 119. Exact Sciences Anal and Colorectal Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 120. Exact Sciences Strategic initiatives
Table 121. Genomictree Profiles
Table 122. Genomictree Anal and Colorectal Cancer Product Introduction
Table 123. Genomictree Anal and Colorectal Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 124. Genomictree Strategic initiatives
Table 125. Immunovaccine Profiles
Table 126. Immunovaccine Anal and Colorectal Cancer Product Introduction
Table 127. Immunovaccine Anal and Colorectal Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 128. Immunovaccine Strategic initiatives
Table 129. ISA Pharmaceuticals Profiles
Table 130. ISA Pharmaceuticals Anal and Colorectal Cancer Product Introduction
Table 131. ISA Pharmaceuticals Anal and Colorectal Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 132. ISA Pharmaceuticals Strategic initiatives
Table 133. Merck Profiles
Table 134. Merck Anal and Colorectal Cancer Product Introduction
Table 135. Merck Anal and Colorectal Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 136. Merck Strategic initiatives
